Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III switch study of dolutegravir plus rilpivirine in virologically suppressed HIV-1 adults
2014-005147-40Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir, rilpivirine in Human immunodeficiency virus infection type 1, sponsored by ViiV Healthcare. Started Apr 2015; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-005147-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005147-40.